RPCEC00000369尚未招募1 期
Safety and efficacy study of the monoclonal antibody nimotuzumab in the treatment of severe patients with SARS-CoV-2 pneumonia. (COVID-19) - NIMO COVID-19
Center of Molecular Immunology (CIM)0 个研究点目标入组 40 人开始时间: 2021年5月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Treatment
入排标准
- 年龄范围
- 19 years 至 one（—）
- 性别
- All
入选标准
- •1.- Any gender and skin color
- •2.- Age equal to or greater than 19 years
- •3.- Patients in a severe stage of COVID-19 of the disease defined by any of the following conditions:
- •- Patients who have SpO2 <94% or patients in need of oxygen therapy to maintain SO2> 93% or
- •- Patients with a PaO2 / FiO2 ratio <300 mm Hg or
- •- Patients with a respiratory rate> 30 inspirations / min,
- •- Patients with infiltrate in more than 50% of both lung fields
排除标准
- •1.- Pregnant or lactating women.
- •2.-Under 19 years.
研究者
相似试验
尚未招募
1 期
imotuzumab cold kit for the immunodiagnosis of solid tumorsLung DiseasesTumors of head and neck, lung and gliomasHead and Neck NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsGliomaRespiratory Tract DiseasesNeoplasms, NeuroepitheliaNeoplasms, Glandular and EpithelialNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueNeuroectodermal TumorsRPCEC00000290Center of Molecular Immunology (CIM)
进行中（未招募）
1 期
Safety, Tolerability and Efficacy of the Therapeutic Antibody Felzartamab in Rejection Late After Kidney Transplantatioate active or chronic active antibody-mediated rejectionEUCTR2021-000545-40-DEMedical University of Vienna20
进行中（未招募）
1 期
Safety, Tolerability and Efficacy of the Therapeutic Antibody Felzartamab in Rejection Late After Kidney Transplantatioate active or chronic active antibody-mediated rejectionEUCTR2021-000545-40-ATMedical University of Vienna22
已完成
不适用
Study for effects of Haemophilus Influenzae type b conjugate vaccine in childreChildren Haemophilus Meningitis.Meningitis due to Haemophilus influenzaeIRCT201008084536N1Masoondarou Co.50
进行中（未招募）
不适用
Trial aimed at evaluating the activity of the anti-ALK1 monoclonal antibody PF-03446962 in relapsed or refractory urothelial cancer (UC) failing first-line treatment.EUCTR2011-005983-12-ITISTITUTO NAZIONALE PER LA CURA TUMORI